Education
About Us
Working with TipRanks
Follow Us
Transmedics Group (TMDX)
:TMDX
TMDX Stock Chart & Stats
$127.67
-$4.08(-5.19%)
At close: 4:00 PM EST
$127.67
-$4.08(-5.19%)
Day’s Range― - ―
52-Week Range$55.00 - $156.00
Previous CloseN/A
Volume1.17M
Average Volume (3M)784.03K
Market Cap
$4.36B
Enterprise Value$4.63B
Total Cash (Recent Filing)$466.17M
Total Debt (Recent Filing)$519.35M
Price to Earnings (P/E)51.6
Beta1.06
Next Earnings
Mar 04, 2026EPS Estimate
0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.66
Shares Outstanding34,174,324
10 Day Avg. Volume774,232
30 Day Avg. Volume784,033
Financial Highlights & Ratios
PEG Ratio-0.24
Price to Book (P/B)9.06
Price to Sales (P/S)4.69
P/FCF Ratio-25.60
Enterprise Value/Market Cap1.06
Enterprise Value/Revenue8.17
Enterprise Value/Gross Profit13.55
Enterprise Value/Ebitda34.97
Forecast
1Y Price Target
$147.80Price Target Upside15.77% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
EPS Forecast (FY)2.59
Revenue Forecast (FY)$600.85M
Bulls Say, Bears Say
Bulls Say
Aviation And Transplant TrendsAviation data shows the potential for an 11% increase in total flights and a 9% increase in flight hours, indicating strong performance.
Market GrowthStrong daily trends in the UNOS market data suggest growth in transplants, supporting TMDX's performance metrics.
Revenue GuidanceManagement raised the midpoint of its revenue guidance, indicating confidence in future performance.
Bears Say
Growth SlowdownRevenue growth slowed to 32% in 3Q25 from 38% in 2Q25.
Revenue ShortfallTMDX delivered revenue slightly short of consensus, which is expected to drive the stock down.
Transplant Volume DeclineA recent decline in organ transplant volumes and a slowdown in TransMedics flight data occurred during the third quarter, likely due to typical seasonality in the transplant industry.
TransMedics Group News
TMDX FAQ
What was Transmedics Group’s price range in the past 12 months?
Transmedics Group lowest stock price was $55.00 and its highest was $156.00 in the past 12 months.
What is Transmedics Group’s market cap?
Transmedics Group’s market cap is $4.36B.
When is Transmedics Group’s upcoming earnings report date?
Transmedics Group’s upcoming earnings report date is Mar 04, 2026 which is in 72 days.
How were Transmedics Group’s earnings last quarter?
Transmedics Group released its earnings results on Oct 29, 2025. The company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.361 by $0.299.
Is Transmedics Group overvalued?
According to Wall Street analysts Transmedics Group’s price is currently Undervalued.
Does Transmedics Group pay dividends?
Transmedics Group does not currently pay dividends.
What is Transmedics Group’s EPS estimate?
Transmedics Group’s EPS estimate is 0.38.
How many shares outstanding does Transmedics Group have?
Transmedics Group has 34,174,324 shares outstanding.
What happened to Transmedics Group’s price movement after its last earnings report?
Transmedics Group reported an EPS of $0.66 in its last earnings report, beating expectations of $0.361. Following the earnings report the stock price went up 1.094%.
Which hedge fund is a major shareholder of Transmedics Group?
Currently, no hedge funds are holding shares in TMDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransMedics Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$147.80 (15.77% Upside)
$147.80 (15.77% Upside)
Blogger Sentiment
Bullish
TMDX Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 89.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $257.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.9%
Last 30 Days ▼ 2.9%
Last 30 Days ▼ 2.9%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
110.92%
12-Months-Change
Fundamentals
Return on Equity
32.48%
Trailing 12-Months
Asset Growth
20.43%
Trailing 12-Months
Company Description
Transmedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its Organ Care System includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for extracorporeal perfusion and preservation of donor hearts; and OCS Liver for the preservation of donor livers. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TMDX Company Deck
TMDX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong year-over-year growth and operational achievements, such as significant revenue growth, improved margins, and international expansion plans. However, there were also challenges including a seasonal slowdown and sequential revenue decline. The overall sentiment is balanced with more highlights than lowlights.View all TMDX earnings summariesTMDX Stock 12 Month Forecast
Average Price Target
$147.80
▲(15.77% Upside)
Technical Analysis
Ownership Overview
3.59% Insiders
40.26% Mutual Funds
23.62% Other Institutional Investors
9.00% Public Companies and Individual Investors